Literature DB >> 20847357

Current assessment of endovascular therapy for infrainguinal arterial occlusive disease in patients with diabetes.

Daniel M Ihnat1, Joseph L Mills.   

Abstract

Endovascular therapy has increasingly become the initial clinical option for the treatment of lower-extremity peripheral arterial occlusive disease not only for patients with claudication but also for those with critical limb ischemia. Despite this major clinical practice paradigm shift, the outcomes of endovascular therapy for peripheral arterial disease are difficult to evaluate and compare with established surgical benchmarks because of the lack of prospective randomized trials, incomplete characterization of indications for intervention, mixing of arterial segments and extent of disease treated, the multiplicity of endovascular therapy techniques used, the exclusion of early treatment failures, crossover to open bypass during follow-up, and the frequent lack of intermediate and long-term patency and limb salvage rates in life-table format. These data limitations are especially problematic when one tries to assess the outcomes of endovascular therapy in patients with diabetes. The purpose of the present article is to succinctly review and objectively analyze available data regarding the results of endovascular therapy in patients with diabetes.

Entities:  

Mesh:

Year:  2010        PMID: 20847357     DOI: 10.7547/1000424

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  2 in total

1.  Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system after first-time lower extremity revascularizations.

Authors:  Jeremy D Darling; John C McCallum; Peter A Soden; Raul J Guzman; Mark C Wyers; Allen D Hamdan; Hence J Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-01-07       Impact factor: 4.268

2.  The Influence of Diabetes Mellitus on the Outcome of Superficial Femoral Artery Recanalization is Debatable.

Authors:  L Rizzo; A D'Andrea; N Stella; P Orlando; M Taurino
Journal:  Transl Med UniSa       Date:  2020-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.